Medicenna Unveils Promising Preclinical Results for Novel Cancer Therapy

The latest announcement is out from Medicenna Therapeutics Corp ( (TSE:MDNA) ).

Medicenna Therapeutics Corp has presented promising preclinical data for MDNA113, a novel tumor-targeted and conditionally activated anti-PD-1-IL-2 bifunctional Superkine, at the 2025 AACR Meeting. MDNA113 is designed to target IL-13Rα2, which is overexpressed in several ‘immunologically cold’ tumors, providing a potentially superior approach compared to existing therapies. The data highlights MDNA113’s ability to enhance tumor targeting and conditional activation, offering a differentiated alternative in the competitive landscape of anti-PD-1-IL-2 therapies, potentially benefiting millions of cancer patients worldwide.

Spark’s Take on TSE:MDNA Stock

According to Spark, TipRanks’ AI Analyst, TSE:MDNA is a Neutral.

Medicenna’s overall score reflects significant financial challenges, with ongoing losses and cash flow issues. However, the company’s low debt levels and promising clinical trial results for MDNA11 provide potential upside. Technical analysis indicates a neutral sentiment, and the valuation underscores the speculative nature of the stock.

To see Spark’s full report on TSE:MDNA stock, click here.

More about Medicenna Therapeutics Corp

Medicenna Therapeutics Corp is a clinical-stage immunotherapy company focused on developing novel, highly selective versions of IL-2, IL-4, and IL-13 Superkines. The company aims to create first-in-class Empowered Superkines for cancer and autoimmune diseases, with products like MDNA11, a next-generation IL-2 Superkine, and bizaxofusp, an IL-4 Empowered Superkine.

YTD Price Performance: -30.82%

Average Trading Volume: 51,917

Technical Sentiment Signal: Buy

Current Market Cap: C$86.04M

See more data about MDNA stock on TipRanks’ Stock Analysis page.